"Neoplasm Grading" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
| Descriptor ID |
D060787
|
| MeSH Number(s) |
E01.789.612
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Grading".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Grading".
This graph shows the total number of publications written about "Neoplasm Grading" by people in this website by year, and whether "Neoplasm Grading" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 21 | 21 |
| 2013 | 1 | 20 | 21 |
| 2014 | 0 | 21 | 21 |
| 2015 | 1 | 24 | 25 |
| 2016 | 1 | 24 | 25 |
| 2017 | 2 | 21 | 23 |
| 2018 | 1 | 24 | 25 |
| 2019 | 4 | 19 | 23 |
| 2020 | 2 | 14 | 16 |
| 2021 | 0 | 10 | 10 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 10 | 10 |
| 2024 | 2 | 10 | 12 |
| 2025 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Grading" by people in Profiles.
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
-
Urothelial carcinoma in situ with "early papillary formation" vs "lateral spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial carcinoma: A survey of pathologist and urologist interpretations. Am J Clin Pathol. 2025 Apr 19; 163(4):629-640.
-
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling. J Natl Cancer Inst. 2025 Apr 01; 117(4):685-691.
-
When is prostate cancer really cancer? J Natl Cancer Inst. 2025 Mar 01; 117(3):402-405.
-
Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 Oct; 34(10):1630-1638.
-
The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis. J Neurooncol. 2025 Feb; 171(3):629-636.
-
Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 10 07; 34(10):1630-1638.
-
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiother Oncol. 2024 Dec; 201:110532.
-
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec; 42(34):4095-4102.